Pelvic relapses in ovarian cancer. Role of CA-125,transvaginal ultrasound and color Doppler

From January 1995 to January 2001, 40 patients with epithelial ovarian cancer were treated at our Institution. Fourteen of these, with a clinical CR after surgery and platinum-based chemotherapy, were evaluated monthly by gynecological examination, Ca-125 RIA assay, pelvic ultrasound with transabdominal and transvaginal probe and color Doppler. Six pelvic relapses, from 1.5 to 3.0 cm, were detected by transvaginal ultrasound (US). They showed a rich neovascularization with low resistance, high flow, PI from 0.3 to 1.0 and RI < 0.5 in all cases. US did not reveal any sign of relapse in the remaining eight patients. In all cases of pelvic relapses ultrasonic signs of recurrence preceded the increase of Ca-125 by one to six months (average 3.8).

Ovarian Cancer; Pelvic relapse; Ca-125; Transvaginal ultrasound

[1] Porsbjerg C.M., Sorensen J.B.: "The role of tumor marker CA-125 in the treatment of ovarian cancer". Ugeskr. Laeger., 1998, 160 (7), 995.

[2] Gard G.B.. Houghton R.S.: "An assessment of the value serum CA-125 measurements in the management of epithelial ovarian carcinoma". Gynecol. Oneal., 1994, 53 (2), 83.

[3] Van der Burg M.E.: "The role of CA-125 in the earlier diagnosis of progressive disease in ovarian cancer". Ann. Oneal., 1990, 1, 301.

[4] Oehler M.K., Sutterlin M., Caffier H.: "CASA and CA-125 in diagnosis and follow-up of advanced ovarian cancer''. Anticancer Res., 1999, 19 (suppl.), 2513.

[5] Wagner U., Kohler S.: "Immunological consolidation of ovanan carcinoma recurrences with monoclonal anti-idiotype antibody ACA 125: immune response and survival in palliative treatment". Clin. Cancer Res., 200 I, 7 (5), 1154.

[6] Konecny G., Untch M.: "Association of Urokinase - type plas1111-nogenactivator and its inhibitor with disease progression and prognosis in ovarian cancer". Clin. Cancer Res., 2001, 7 (6), 1743.

[7] Guerriero S., Ajossa S., Risalvato A., Lai M.P., Mais Y., Angiolucci M., Melis G.B.: "Diagnosis of adnexal malignancies by using color Doppler energy imaging as a secondary test in persistent masses". Ultrasound Obstet. Gynecol., 1998, 4, 277.

[8] Alcazar J.L., Errasti T., Zornoza A., Minguez J.A., Galan M.J.: "Transvaginal color Doppler ultrasonography and CA-125 in suspicious adnexal masses". Int. J. Gynecol. Obstet., 1999, 66 (3), 255.

[9] Schneider Y.L., Reed A.K.L, Hatch K.D.: "Comparison of Doppler with two dimensional sonography and CA-125 for prediction of malignancy of pelvic masses". Obstet. Gynecol., 1993 (81), 983.

[10] Bromely, Goodman H., Benacerraf B.R.: "Comparison between sonographic morphology and Doppler waveform for the diagnosis of ovarian malignancy". Obstet. Gynecol., 1994 (83), 434.

[11] Laframboise S., Nedelw R.: "Use of CA-125 and ultrasound in high risk women". Int. J. Gyneco/. Cancer, 2002, 12 (1), 86.

[12] Wan X., Suy: "Color Doppler ultrasound and quantitative histologic study of angiogenesis in ovarian tumor". Zhonghua Yi Xue Za Zhi, 2000, 80 (9), 672.

[13] Allen D.J., Baak J., Belpomme D., Berek J.S., Bertelse K., Ten Bokkel H. et al.: "Advanced epithelial ovarian cancer, 1993 consensus Statements". Ann. Oneal., 1993 (suppl.), 4, 83.

[14] Folkman J., Ingber D.: "Inhibition of angiogenesis". Semtn. Cancer Biol., 1992 (3), 89.

[15] Folkman J.: "Angiogenesis research: from laboratory to clinic". Forum (Genova) 1999, 9 (suppl.) 3, 59.

[16] Maggino T., Gadducci A.: " Serum markers as prognostic factor m epithelial ovarian cancer: an overview". Eu,: J. Gynaecol. Oneal., 2000, 21 (1), 64.

[17] Magiani F., Fazio F.: "Diagnosis of persistent ovarian carcinoma with three step immunoscintigraphy". Br. J. Cancer. 2000, 82(3), 616.

[18] Markmann M.: " Resetting CA-125 range for a complete response to chemotherapy, why?". Gynecol. Oneal., 1994 (53), 281.